Cargando…
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
Autores principales: | Vaduganathan, Muthiah, Vardeny, Orly, Michel, Thomas, McMurray, John J.V., Pfeffer, Marc A., Solomon, Scott D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121452/ https://www.ncbi.nlm.nih.gov/pubmed/32227760 http://dx.doi.org/10.1056/NEJMsr2005760 |
Ejemplares similares
-
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022) -
META-ANALYSIS OF SAFETY AND EFFICACY OF RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITORS IN COVID-19 POPULATION
por: Sattar, Yasar, et al.
Publicado: (2021) -
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020) -
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020) -
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)